Trials / Conditions / Lymphatic Diseases

Lymphatic Diseases

21 registered clinical trials studyying Lymphatic Diseases — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Completed	Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders NCT06267807	Radboud University Medical Center	N/A
Recruiting	A Prospective Natural History Study of Lymphatic Anomalies NCT05731141	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	—
Withdrawn	A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT05431179	Oncternal Therapeutics, Inc	Phase 3
Active Not Recruiting	Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma NCT05263583	Cothera Bioscience, Inc	Phase 2
Active Not Recruiting	Lymphaticovenous Anastomosis as Treatment for Lymphedema NCT05441943	Odense University Hospital	N/A
Completed	Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial NCT05683444	Rigshospitalet, Denmark	EARLY_Phase 1
Active Not Recruiting	Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma NCT03696784	UNC Lineberger Comprehensive Cancer Center	Phase 1
Active Not Recruiting	Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL NCT03602157	UNC Lineberger Comprehensive Cancer Center	Phase 1
Completed	A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymp NCT03744676	Juno Therapeutics, a Subsidiary of Celgene	Phase 2
Active Not Recruiting	BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma NCT03264131	UNC Lineberger Comprehensive Cancer Center	Phase 2
Completed	"Effects of Manual Lymphatic Drainage in the Neck in Healthy Subjects. Experimental Randomized Crossover Study NCT03709407	Universidad Europea de Madrid	N/A
Unknown	Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma ( NCT03373019	Fudan University	Phase 2
Completed	Micro-mobile Foot Compression and Diabetic Foot NCT03135535	Baylor College of Medicine	Phase 2
Active Not Recruiting	Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL NCT02690545	UNC Lineberger Comprehensive Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Administration of T Lymphocytes for Prevention of Relapse of Lymphomas NCT02663297	UNC Lineberger Comprehensive Cancer Center	Phase 1
Completed	Imaging of Lymphatic Anomalies NCT02744027	Children's Hospital of Philadelphia	N/A
Terminated	Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting NCT02499627	Fondazione Italiana Linfomi - ETS	Phase 2
Completed	Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Pa NCT02497131	Fondazione Italiana Linfomi - ETS	Phase 2
Completed	Sildenafil for the Treatment of Lymphatic Malformations NCT02335242	Stanford University	Phase 2
Completed	Effectiveness of Intracavitary Manual Lymphatic Drainage NCT02960841	Universidad Europea de Madrid	Phase 4
Recruiting	Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units NCT01451502	Masonic Cancer Center, University of Minnesota	N/A